http://www.biocentury.com/rss/weekinreviewWeek in Reviewen-US© Copyright 2012 BioCentury, Inc.RSS Generatorhttp://www.biocentury.com/Data/NewsCenter2/Images/WeekInReview/Coverstory.gifhttp://www.biocentury.com/rss/weekinreviewhttp://www.biocentury.com/weekinreview/deals/2012-05-14/aeras-idri-deal-279421http://www.biocentury.com/weekinreview/deals/2012-05-14/aeras-idri-deal-279421DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/aeterna-zentaris-keryx-deal-279422http://www.biocentury.com/weekinreview/deals/2012-05-14/aeterna-zentaris-keryx-deal-279422DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/affymetrix-ebioscience-deal-279423http://www.biocentury.com/weekinreview/deals/2012-05-14/affymetrix-ebioscience-deal-279423DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/allos-spectrum-pharmaceuticals-deal-279424http://www.biocentury.com/weekinreview/deals/2012-05-14/allos-spectrum-pharmaceuticals-deal-279424DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/amnisure-international-llc-qiagen-deal-279425http://www.biocentury.com/weekinreview/deals/2012-05-14/amnisure-international-llc-qiagen-deal-279425DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/axiom-molecular-pty-ltd-university-of-queensland-deal-279426http://www.biocentury.com/weekinreview/deals/2012-05-14/axiom-molecular-pty-ltd-university-of-queensland-deal-279426DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/coherus-biosciences-daiichi-sankyo-deal-279427http://www.biocentury.com/weekinreview/deals/2012-05-14/coherus-biosciences-daiichi-sankyo-deal-279427DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/depomed-ironwood-deal-279428http://www.biocentury.com/weekinreview/deals/2012-05-14/depomed-ironwood-deal-279428DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/emergent-biosolutions-pfizer-deal-279429http://www.biocentury.com/weekinreview/deals/2012-05-14/emergent-biosolutions-pfizer-deal-279429DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/enzon-zhejiang-hisun-pharmaceutical-deal-279430http://www.biocentury.com/weekinreview/deals/2012-05-14/enzon-zhejiang-hisun-pharmaceutical-deal-279430DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/evotec-4-antibody-deal-279431http://www.biocentury.com/weekinreview/deals/2012-05-14/evotec-4-antibody-deal-279431DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/fluidigm-broad-institute-deal-279432http://www.biocentury.com/weekinreview/deals/2012-05-14/fluidigm-broad-institute-deal-279432DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/fluidigm-novartis-deal-279433http://www.biocentury.com/weekinreview/deals/2012-05-14/fluidigm-novartis-deal-279433DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/genetic-technologies-neogen-deal-279434http://www.biocentury.com/weekinreview/deals/2012-05-14/genetic-technologies-neogen-deal-279434DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/glycomimetics-glycosensors-and-diagnostics-llc-international-aids-vaccine-initiative-(iavi)-deal-279435http://www.biocentury.com/weekinreview/deals/2012-05-14/glycomimetics-glycosensors-and-diagnostics-llc-international-aids-vaccine-initiative-(iavi)-deal-279435DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/hematech-biotherapeutics-inc-prometic-deal-279436http://www.biocentury.com/weekinreview/deals/2012-05-14/hematech-biotherapeutics-inc-prometic-deal-279436DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/human-genome-sciences-glaxosmithkline-deal-279437http://www.biocentury.com/weekinreview/deals/2012-05-14/human-genome-sciences-glaxosmithkline-deal-279437DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/intellect-neurosciences-northwestern-university-deal-279438http://www.biocentury.com/weekinreview/deals/2012-05-14/intellect-neurosciences-northwestern-university-deal-279438DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/islet-sciences-yale-university-deal-279439http://www.biocentury.com/weekinreview/deals/2012-05-14/islet-sciences-yale-university-deal-279439DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/kentucky-bioprocessing-llc-mapp-biopharmaceutical-nomad-bioscience-gmbh-deal-279440http://www.biocentury.com/weekinreview/deals/2012-05-14/kentucky-bioprocessing-llc-mapp-biopharmaceutical-nomad-bioscience-gmbh-deal-279440DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/ligand-merck-kgaa-deal-279441http://www.biocentury.com/weekinreview/deals/2012-05-14/ligand-merck-kgaa-deal-279441DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/ligand-vertex-deal-279442http://www.biocentury.com/weekinreview/deals/2012-05-14/ligand-vertex-deal-279442DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/multiplicom-hopital-pitie-salpetriere-deal-279443http://www.biocentury.com/weekinreview/deals/2012-05-14/multiplicom-hopital-pitie-salpetriere-deal-279443DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/nuevolution-boehringer-ingelheim-deal-279444http://www.biocentury.com/weekinreview/deals/2012-05-14/nuevolution-boehringer-ingelheim-deal-279444DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/precision-dermatology-triax-pharmaceuticals-llc-deal-279445http://www.biocentury.com/weekinreview/deals/2012-05-14/precision-dermatology-triax-pharmaceuticals-llc-deal-279445DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/proteostasis-cystic-fibrosis-foundation-deal-279446http://www.biocentury.com/weekinreview/deals/2012-05-14/proteostasis-cystic-fibrosis-foundation-deal-279446DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/regenesance-als-therapy-development-institute-(als-tdi)-deal-279447http://www.biocentury.com/weekinreview/deals/2012-05-14/regenesance-als-therapy-development-institute-(als-tdi)-deal-279447DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/smith-and-nephew-deal-279448http://www.biocentury.com/weekinreview/deals/2012-05-14/smith-and-nephew-deal-279448DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/valeant-pharmaceuticals-university-medical-pharmaceuticals-corp-deal-279449http://www.biocentury.com/weekinreview/deals/2012-05-14/valeant-pharmaceuticals-university-medical-pharmaceuticals-corp-deal-279449DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/deals/2012-05-14/xcellerex-general-electric-deal-279450http://www.biocentury.com/weekinreview/deals/2012-05-14/xcellerex-general-electric-deal-279450DealsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/ariosa-diagnostics-labcorp-sales-and-marketing-update-279509http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/ariosa-diagnostics-labcorp-sales-and-marketing-update-279509Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/assurerx-sales-and-marketing-update-279510http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/assurerx-sales-and-marketing-update-279510Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/bayer-santen-sales-and-marketing-update-279511http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/bayer-santen-sales-and-marketing-update-279511Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/bial-portela-medigene-sales-and-marketing-update-279512http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/bial-portela-medigene-sales-and-marketing-update-279512Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/biosyent-inc-pharmazeutische-fabrik-montavit-gesmbh-sales-and-marketing-update-279513http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/biosyent-inc-pharmazeutische-fabrik-montavit-gesmbh-sales-and-marketing-update-279513Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/blandh-clinigen-group-hospira-astrazeneca-sales-and-marketing-update-279514http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/blandh-clinigen-group-hospira-astrazeneca-sales-and-marketing-update-279514Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/desitin-pozen-sales-and-marketing-update-279515http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/desitin-pozen-sales-and-marketing-update-279515Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/dnaform-source-bioscience-plc-sales-and-marketing-update-279516http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/dnaform-source-bioscience-plc-sales-and-marketing-update-279516Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/mitsubishi-tanabe-pharma-sales-and-marketing-update-279517http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/mitsubishi-tanabe-pharma-sales-and-marketing-update-279517Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/pathway-genomics-sales-and-marketing-update-279518http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/pathway-genomics-sales-and-marketing-update-279518Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/teva-sales-and-marketing-update-279519http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/teva-sales-and-marketing-update-279519Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/valeant-pharmaceuticals-glaxosmithkline-sales-and-marketing-update-279520http://www.biocentury.com/weekinreview/salesmarketing/2012-05-14/valeant-pharmaceuticals-glaxosmithkline-sales-and-marketing-update-279520Sales and MarketingMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/amag-pharmaceuticals-management-update-279338http://www.biocentury.com/weekinreview/management/2012-05-14/amag-pharmaceuticals-management-update-279338ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/biocancell-management-update-279339http://www.biocentury.com/weekinreview/management/2012-05-14/biocancell-management-update-279339ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/biomarin-pharmaceuticals-inc-management-update-279340http://www.biocentury.com/weekinreview/management/2012-05-14/biomarin-pharmaceuticals-inc-management-update-279340ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/bio-matrix-scientific-management-update-279341http://www.biocentury.com/weekinreview/management/2012-05-14/bio-matrix-scientific-management-update-279341ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/celgene-management-update-279342http://www.biocentury.com/weekinreview/management/2012-05-14/celgene-management-update-279342ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/dbv-management-update-279343http://www.biocentury.com/weekinreview/management/2012-05-14/dbv-management-update-279343ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/egalet-management-update-279344http://www.biocentury.com/weekinreview/management/2012-05-14/egalet-management-update-279344ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/five-prime-management-update-279345http://www.biocentury.com/weekinreview/management/2012-05-14/five-prime-management-update-279345ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/f-star-management-update-279346http://www.biocentury.com/weekinreview/management/2012-05-14/f-star-management-update-279346ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/health-diagnostic-laboratory-management-update-279347http://www.biocentury.com/weekinreview/management/2012-05-14/health-diagnostic-laboratory-management-update-279347ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/incline-therapeutics-management-update-279349http://www.biocentury.com/weekinreview/management/2012-05-14/incline-therapeutics-management-update-279349ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/innopharma-management-update-279350http://www.biocentury.com/weekinreview/management/2012-05-14/innopharma-management-update-279350ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/lundbeck-management-update-279348http://www.biocentury.com/weekinreview/management/2012-05-14/lundbeck-management-update-279348ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/population-genetics-technologies-inc-management-update-279351http://www.biocentury.com/weekinreview/management/2012-05-14/population-genetics-technologies-inc-management-update-279351ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/ruga-management-update-279352http://www.biocentury.com/weekinreview/management/2012-05-14/ruga-management-update-279352ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/rxi-pharmaceuticals-management-update-279353http://www.biocentury.com/weekinreview/management/2012-05-14/rxi-pharmaceuticals-management-update-279353ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/synthon-management-update-279354http://www.biocentury.com/weekinreview/management/2012-05-14/synthon-management-update-279354ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/teva-management-update-279355http://www.biocentury.com/weekinreview/management/2012-05-14/teva-management-update-279355ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/ziopharm-management-update-279356http://www.biocentury.com/weekinreview/management/2012-05-14/ziopharm-management-update-279356ManagementMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/abbott-neurology-news-279521http://www.biocentury.com/weekinreview/othercompany/2012-05-14/abbott-neurology-news-279521Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/actelion-pharmaceuticals-news-279522http://www.biocentury.com/weekinreview/othercompany/2012-05-14/actelion-pharmaceuticals-news-279522Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/amag-pharmaceuticals-hematology-news-279523http://www.biocentury.com/weekinreview/othercompany/2012-05-14/amag-pharmaceuticals-hematology-news-279523Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/angel-biotech-supplyservice-news-279524http://www.biocentury.com/weekinreview/othercompany/2012-05-14/angel-biotech-supplyservice-news-279524Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/ark-therapeutics-university-college-london-endocrinemetabolic-news-279525http://www.biocentury.com/weekinreview/othercompany/2012-05-14/ark-therapeutics-university-college-london-endocrinemetabolic-news-279525Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/biolex-infectious-news-279526http://www.biocentury.com/weekinreview/othercompany/2012-05-14/biolex-infectious-news-279526Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/bio-matrix-scientific-genecell-therapy-news-279527http://www.biocentury.com/weekinreview/othercompany/2012-05-14/bio-matrix-scientific-genecell-therapy-news-279527Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/catalent-pharma-profectus-infectious-biomanufacturing-news-279528http://www.biocentury.com/weekinreview/othercompany/2012-05-14/catalent-pharma-profectus-infectious-biomanufacturing-news-279528Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/china-nuokang-hematology-cardiovascular-news-279529http://www.biocentury.com/weekinreview/othercompany/2012-05-14/china-nuokang-hematology-cardiovascular-news-279529Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/helicos-pacific-biosciences-genomics-news-279530http://www.biocentury.com/weekinreview/othercompany/2012-05-14/helicos-pacific-biosciences-genomics-news-279530Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/innovative-medicines-initiative-(imi)-juvenile-diabetes-research-foundation-international-(jdrf)-en-279531http://www.biocentury.com/weekinreview/othercompany/2012-05-14/innovative-medicines-initiative-(imi)-juvenile-diabetes-research-foundation-international-(jdrf)-en-279531Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/isogenica-high-throughput-screening-news-279532http://www.biocentury.com/weekinreview/othercompany/2012-05-14/isogenica-high-throughput-screening-news-279532Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/kineta-university-of-washington-university-of-texas-medical-branch-infectious-news-279533http://www.biocentury.com/weekinreview/othercompany/2012-05-14/kineta-university-of-washington-university-of-texas-medical-branch-infectious-news-279533Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/porphylix-hematology-news-279534http://www.biocentury.com/weekinreview/othercompany/2012-05-14/porphylix-hematology-news-279534Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/qiagen-bill-and-melinda-gates-foundation-grand-challenges-canada-diagnostic-news-279535http://www.biocentury.com/weekinreview/othercompany/2012-05-14/qiagen-bill-and-melinda-gates-foundation-grand-challenges-canada-diagnostic-news-279535Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/repligen-diagnostic-news-279536http://www.biocentury.com/weekinreview/othercompany/2012-05-14/repligen-diagnostic-news-279536Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/othercompany/2012-05-14/takeda-gastrointestinal-news-279537http://www.biocentury.com/weekinreview/othercompany/2012-05-14/takeda-gastrointestinal-news-279537Other NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/affitech-board-of-directors-update-279335http://www.biocentury.com/weekinreview/management/2012-05-14/affitech-board-of-directors-update-279335Boards of DirectorsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/biocancell-board-of-directors-update-279336http://www.biocentury.com/weekinreview/management/2012-05-14/biocancell-board-of-directors-update-279336Boards of DirectorsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/management/2012-05-14/celladon-board-of-directors-update-279337http://www.biocentury.com/weekinreview/management/2012-05-14/celladon-board-of-directors-update-279337Boards of DirectorsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/androxal-enclomiphene-regulatory-update-279381http://www.biocentury.com/weekinreview/regulatory/2012-05-14/androxal-enclomiphene-regulatory-update-279381RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/arcalyst-rilonacept-regulatory-update-279380http://www.biocentury.com/weekinreview/regulatory/2012-05-14/arcalyst-rilonacept-regulatory-update-279380RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/bg-12-regulatory-update-279364http://www.biocentury.com/weekinreview/regulatory/2012-05-14/bg-12-regulatory-update-279364RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/botox-onabotulinumtoxina-regulatory-update-279359http://www.biocentury.com/weekinreview/regulatory/2012-05-14/botox-onabotulinumtoxina-regulatory-update-279359RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/defibrotide-regulatory-update-279369http://www.biocentury.com/weekinreview/regulatory/2012-05-14/defibrotide-regulatory-update-279369RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/erivedge-vismodegib-regulatory-update-279367http://www.biocentury.com/weekinreview/regulatory/2012-05-14/erivedge-vismodegib-regulatory-update-279367RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/giazo-balsalazide-tablet-regulatory-update-279382http://www.biocentury.com/weekinreview/regulatory/2012-05-14/giazo-balsalazide-tablet-regulatory-update-279382RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/halofuginone-regulatory-update-279374http://www.biocentury.com/weekinreview/regulatory/2012-05-14/halofuginone-regulatory-update-279374RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/iluvien-regulatory-update-279358http://www.biocentury.com/weekinreview/regulatory/2012-05-14/iluvien-regulatory-update-279358RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/jevtana-cabazitaxel-regulatory-update-279383http://www.biocentury.com/weekinreview/regulatory/2012-05-14/jevtana-cabazitaxel-regulatory-update-279383RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/latuda-lurasidone-regulatory-update-279368http://www.biocentury.com/weekinreview/regulatory/2012-05-14/latuda-lurasidone-regulatory-update-279368RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/linsitinib-regulatory-update-279361http://www.biocentury.com/weekinreview/regulatory/2012-05-14/linsitinib-regulatory-update-279361RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/lorcaserin-regulatory-update-279360http://www.biocentury.com/weekinreview/regulatory/2012-05-14/lorcaserin-regulatory-update-279360RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/luviva-advanced-cervical-scan-regulatory-update-279372http://www.biocentury.com/weekinreview/regulatory/2012-05-14/luviva-advanced-cervical-scan-regulatory-update-279372RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/marqibo-vincristine-regulatory-update-279384http://www.biocentury.com/weekinreview/regulatory/2012-05-14/marqibo-vincristine-regulatory-update-279384RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/pixuvri-pixantrone-regulatory-update-279366http://www.biocentury.com/weekinreview/regulatory/2012-05-14/pixuvri-pixantrone-regulatory-update-279366RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/pliaglis-regulatory-update-279378http://www.biocentury.com/weekinreview/regulatory/2012-05-14/pliaglis-regulatory-update-279378RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/quad-elvitegravircobicistatemtricitabinetenofovir-regulatory-update-279371http://www.biocentury.com/weekinreview/regulatory/2012-05-14/quad-elvitegravircobicistatemtricitabinetenofovir-regulatory-update-279371RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/rasilamlo-regulatory-update-279377http://www.biocentury.com/weekinreview/regulatory/2012-05-14/rasilamlo-regulatory-update-279377RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/remicade-infliximab-regulatory-update-279376http://www.biocentury.com/weekinreview/regulatory/2012-05-14/remicade-infliximab-regulatory-update-279376RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/revlimid-lenalidomide-regulatory-update-279365http://www.biocentury.com/weekinreview/regulatory/2012-05-14/revlimid-lenalidomide-regulatory-update-279365RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/sativex-regulatory-update-279373http://www.biocentury.com/weekinreview/regulatory/2012-05-14/sativex-regulatory-update-279373RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/seven-day-contraceptive-patch-regulatory-update-279357http://www.biocentury.com/weekinreview/regulatory/2012-05-14/seven-day-contraceptive-patch-regulatory-update-279357RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/somatuline-depot-regulatory-update-279375http://www.biocentury.com/weekinreview/regulatory/2012-05-14/somatuline-depot-regulatory-update-279375RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/tarceva-erlotinib-regulatory-update-279362http://www.biocentury.com/weekinreview/regulatory/2012-05-14/tarceva-erlotinib-regulatory-update-279362RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/tofacitinib-regulatory-update-279379http://www.biocentury.com/weekinreview/regulatory/2012-05-14/tofacitinib-regulatory-update-279379RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/trobalt-retigabine-regulatory-update-279385http://www.biocentury.com/weekinreview/regulatory/2012-05-14/trobalt-retigabine-regulatory-update-279385RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/truvada-emtricitabinetenofovir-regulatory-update-279370http://www.biocentury.com/weekinreview/regulatory/2012-05-14/truvada-emtricitabinetenofovir-regulatory-update-279370RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/regulatory/2012-05-14/xarelto-rivaroxaban-regulatory-update-279363http://www.biocentury.com/weekinreview/regulatory/2012-05-14/xarelto-rivaroxaban-regulatory-update-279363RegulatoryMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/4-factor-prothrombin-complex-concentrate-phase-iiib-data-279391http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/4-factor-prothrombin-complex-concentrate-phase-iiib-data-279391Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/acu-4429-interim-phase-iia-data-279386http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/acu-4429-interim-phase-iia-data-279386Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/adcetris-brentuximab-vedotin-interim-phase-ii-data-279414http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/adcetris-brentuximab-vedotin-interim-phase-ii-data-279414Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/aerovanc-phase-ia-data-279413http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/aerovanc-phase-ia-data-279413Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/aripiprazole-im-depot-formulation-additional-phase-iii-data-279397http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/aripiprazole-im-depot-formulation-additional-phase-iii-data-279397Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/asm8-phase-iia-data-279408http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/asm8-phase-iia-data-279408Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/atx-101-additional-phase-iii-data-279402http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/atx-101-additional-phase-iii-data-279402Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/beposone-phase-ii-data-279400http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/beposone-phase-ii-data-279400Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/ctap101-phase-iib-data-279392http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/ctap101-phase-iib-data-279392Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/curexcell-phase-iv-data-279403http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/curexcell-phase-iv-data-279403Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/dalcetrapib-development-discontinued-279401http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/dalcetrapib-development-discontinued-279401Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/fluzone-quadrivalent-phase-iii-data-279412http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/fluzone-quadrivalent-phase-iii-data-279412Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/hemopurifier-additional-data-279387http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/hemopurifier-additional-data-279387Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/hgh-ctp-extension-study-data-279411http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/hgh-ctp-extension-study-data-279411Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/house-dust-mites-sublingual-immunotherapy-tablet-phase-ii-data-279415http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/house-dust-mites-sublingual-immunotherapy-tablet-phase-ii-data-279415Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/htu-520-phase-iii-data-279399http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/htu-520-phase-iii-data-279399Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/latuda-lurasidone-additional-phase-iii-data-279394http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/latuda-lurasidone-additional-phase-iii-data-279394Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/latuda-lurasidone-additional-phase-iii-data-279395http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/latuda-lurasidone-additional-phase-iii-data-279395Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/lu-aa21004-phase-iii-data-279398http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/lu-aa21004-phase-iii-data-279398Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/mva-hpv-il2-development-discontinued-279418http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/mva-hpv-il2-development-discontinued-279418Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/ndv-3-phase-i-data-279406http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/ndv-3-phase-i-data-279406Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/neurostar-neurology-data-279405http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/neurostar-neurology-data-279405Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/pmx-60056-development-discontinued-279409http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/pmx-60056-development-discontinued-279409Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/pmx-60056-development-discontinued-279410http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/pmx-60056-development-discontinued-279410Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/pradaxa-postmarketing-study-data-279390http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/pradaxa-postmarketing-study-data-279390Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/seven-day-contraceptive-patch-phase-iii-data-279388http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/seven-day-contraceptive-patch-phase-iii-data-279388Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/signifor-pasireotide-additional-phase-iii-data-279407http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/signifor-pasireotide-additional-phase-iii-data-279407Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/sl-701-cancer-data-279416http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/sl-701-cancer-data-279416Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/sun11031-development-discontinued-279393http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/sun11031-development-discontinued-279393Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/tmc435-additional-phase-iib-data-279404http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/tmc435-additional-phase-iib-data-279404Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/truvada-emtricitabinetenofovir-infectious-data-279396http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/truvada-emtricitabinetenofovir-infectious-data-279396Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/v81444-phase-i-data-279419http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/v81444-phase-i-data-279419Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/vedolizumab-phase-iii-data-279417http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/vedolizumab-phase-iii-data-279417Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/veristrat-diagnostic-data-279389http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/veristrat-diagnostic-data-279389Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/vx-809-additional-phase-ii-data-279420http://www.biocentury.com/weekinreview/clinicalresults/2012-05-14/vx-809-additional-phase-ii-data-279420Clinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2012-05-14/amakem-preclinical-data-279451http://www.biocentury.com/weekinreview/preclinical/2012-05-14/amakem-preclinical-data-279451Preclinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2012-05-14/eleven-biotherapeutics-preclinical-data-279452http://www.biocentury.com/weekinreview/preclinical/2012-05-14/eleven-biotherapeutics-preclinical-data-279452Preclinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2012-05-14/genocea-preclinical-data-279453http://www.biocentury.com/weekinreview/preclinical/2012-05-14/genocea-preclinical-data-279453Preclinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2012-05-14/immunocore-preclinical-data-279454http://www.biocentury.com/weekinreview/preclinical/2012-05-14/immunocore-preclinical-data-279454Preclinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2012-05-14/immunocore-preclinical-data-279455http://www.biocentury.com/weekinreview/preclinical/2012-05-14/immunocore-preclinical-data-279455Preclinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2012-05-14/mirna-preclinical-data-279456http://www.biocentury.com/weekinreview/preclinical/2012-05-14/mirna-preclinical-data-279456Preclinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2012-05-14/promedior-preclinical-data-279457http://www.biocentury.com/weekinreview/preclinical/2012-05-14/promedior-preclinical-data-279457Preclinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/preclinical/2012-05-14/senesco-preclinical-data-279458http://www.biocentury.com/weekinreview/preclinical/2012-05-14/senesco-preclinical-data-279458Preclinical ResultsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/212pb-tcmc-trastuzumab-phase-i-started-279463http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/212pb-tcmc-trastuzumab-phase-i-started-279463Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/ah5n1-avian-influenza-vaccine-phase-i-started-279472http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/ah5n1-avian-influenza-vaccine-phase-i-started-279472Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/ach-3102-phase-i-started-279459http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/ach-3102-phase-i-started-279459Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/adcetris-brentuximab-vedotin-phase-iii-started-279476http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/adcetris-brentuximab-vedotin-phase-iii-started-279476Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/adxs-hpv-phase-iii-started-279460http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/adxs-hpv-phase-iii-started-279460Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/ald403-phase-i-started-279461http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/ald403-phase-i-started-279461Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/arikace-development-ongoing-279468http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/arikace-development-ongoing-279468Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/capesaris-phase-ii-start-279467http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/capesaris-phase-ii-start-279467Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/digital-pcr-assays-update-279477http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/digital-pcr-assays-update-279477Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/f-627-phase-ii-started-279464http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/f-627-phase-ii-started-279464Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/human-neural-stem-cells-phase-i-ongoing-279471http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/human-neural-stem-cells-phase-i-ongoing-279471Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/imetelstat-completed-phase-ii-enrollment-279466http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/imetelstat-completed-phase-ii-enrollment-279466Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/isis-apociiirx-phase-ii-started-279469http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/isis-apociiirx-phase-ii-started-279469Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/oral-rigosertib-phase-ii-started-279474http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/oral-rigosertib-phase-ii-started-279474Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/perindoprilamlodipine-phase-iii-started-279478http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/perindoprilamlodipine-phase-iii-started-279478Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/pf-05280586-phase-iii-started-279475http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/pf-05280586-phase-iii-started-279475Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/tesetaxel-phase-ii-started-279465http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/tesetaxel-phase-ii-started-279465Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/travoprost-loaded-punctum-plug-update-279473http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/travoprost-loaded-punctum-plug-update-279473Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/venilon-phase-ii-started-279470http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/venilon-phase-ii-started-279470Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/vrs-317-completed-phase-i-enrollment-279462http://www.biocentury.com/weekinreview/clinicalstatus/2012-05-14/vrs-317-completed-phase-i-enrollment-279462Clinical StatusMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-arcdia-ltd-completes-venture-financing-279479http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-arcdia-ltd-completes-venture-financing-279479Completed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-cytovas-completes-venture-financing-279480http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-cytovas-completes-venture-financing-279480Completed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-cyvek-completes-venture-financing-279481http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-cyvek-completes-venture-financing-279481Completed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-dynavax-completes-follow-on-279482http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-dynavax-completes-follow-on-279482Completed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-egalet-completes-venture-financing-279483http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-egalet-completes-venture-financing-279483Completed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-merus-labs-international-completes-follow-on-279484http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-merus-labs-international-completes-follow-on-279484Completed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-prolor-completes-follow-on-279485http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-prolor-completes-follow-on-279485Completed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-retrophin-completes-venture-financing-279486http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-retrophin-completes-venture-financing-279486Completed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-savient-completes-private-placement-of-units-279487http://www.biocentury.com/weekinreview/offerings/2012-05-14/completedofferings-savient-completes-private-placement-of-units-279487Completed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/proposedofferings-exonhit-proposes-private-placement-279488http://www.biocentury.com/weekinreview/offerings/2012-05-14/proposedofferings-exonhit-proposes-private-placement-279488Proposed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/proposedofferings-intercell-proposes-debt-financing-279490http://www.biocentury.com/weekinreview/offerings/2012-05-14/proposedofferings-intercell-proposes-debt-financing-279490Proposed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/proposedofferings-intercell-proposes-private-placement-279489http://www.biocentury.com/weekinreview/offerings/2012-05-14/proposedofferings-intercell-proposes-private-placement-279489Proposed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/proposedofferings-lorus-proposes-private-placement-of-units-279491http://www.biocentury.com/weekinreview/offerings/2012-05-14/proposedofferings-lorus-proposes-private-placement-of-units-279491Proposed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/proposedofferings-oncomed-proposes-ipo-279492http://www.biocentury.com/weekinreview/offerings/2012-05-14/proposedofferings-oncomed-proposes-ipo-279492Proposed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/withdrawnofferings-genesis-biopharma-withdraws-follow-on-279495http://www.biocentury.com/weekinreview/offerings/2012-05-14/withdrawnofferings-genesis-biopharma-withdraws-follow-on-279495Withdrawn OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/postponedofferings-rib-x-postpones-ipo-279494http://www.biocentury.com/weekinreview/offerings/2012-05-14/postponedofferings-rib-x-postpones-ipo-279494Postponed OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/amendedofferings-cancer-genetics-amends-ipo-279493http://www.biocentury.com/weekinreview/offerings/2012-05-14/amendedofferings-cancer-genetics-amends-ipo-279493Amended OfferingsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-ab-science-financial-update-279496http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-ab-science-financial-update-279496Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-biostem-us-financial-update-279497http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-biostem-us-financial-update-279497Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-cardiome-pharma-corp-financial-update-279498http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-cardiome-pharma-corp-financial-update-279498Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-celladon-financial-update-279499http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-celladon-financial-update-279499Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-eleven-biotherapeutics-financial-update-279500http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-eleven-biotherapeutics-financial-update-279500Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-emergent-biosolutions-financial-update-279501http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-emergent-biosolutions-financial-update-279501Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-entremed-financial-update-279502http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-entremed-financial-update-279502Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-new-enterprise-associates-financial-update-279503http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-new-enterprise-associates-financial-update-279503Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-osta-biotechnologies-financial-update-279504http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-osta-biotechnologies-financial-update-279504Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-oxford-finance-llc-financial-update-279505http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-oxford-finance-llc-financial-update-279505Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-sutro-financial-update-279506http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-sutro-financial-update-279506Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-teva-financial-update-279507http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-teva-financial-update-279507Other Financial NewsMon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-tranzyme-financial-update-279508http://www.biocentury.com/weekinreview/offerings/2012-05-14/otherfinancialnews-tranzyme-financial-update-279508Other Financial NewsMon, 14 May 2012 00:00:00 -0700